Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer
- PMID:23109696
- DOI: 10.1200/JCO.2012.42.8771
Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer
Abstract
Purpose: The ACCORD 12 trial investigated the value of two different preoperative chemoradiotherapy (CT-RT) regimens in T3-4 Nx M0 resectable rectal cancer. Clinical results are reported after follow-up of 3 years.
Patients and methods: Between November 2005 and July 2008, a total of 598 patients were randomly assigned to preoperative CT-RT with CAP45 (45-Gy RT for 5 weeks with concurrent capecitabine) or CAPOX50 (50-Gy RT for 5 weeks with concurrent capecitabine and oxaliplatin). Total mesorectal excision was planned 6 weeks after CT-RT. The primary end point was sterilization of the operative specimen, which was achieved in 13.9% versus 19.2% of patients, respectively (P = .09). Clinical results were analyzed for all randomly assigned patients according to the intention-to-treat principle.
Results: At 3 years, there was no significant difference between CAP45 and CAPOX50 (cumulative incidence of local recurrence, 6.1% v 4.4%; overall survival, 87.6% v 88.3%; disease-free survival, 67.9% v 72.7%). Grade 3 to 4 toxicity was reported in four patients in the CAP45 group and in two patients in the CAPOX50 group. Bowel continence, erectile dysfunction, and social life disturbance were not different between groups. In multivariate analysis, the sterilization rate (Dworak score) of the operative specimen was the main significant prognostic factor (hazard ratio, 0.32; 95% CI, 0.21 to 0.50).
Conclusion: At 3 years, no significant difference in clinical outcome was achieved with the intensified CAPOX regimen. When compared with other recent randomized trials, these results indicate that concurrent administration of oxaliplatin and RT is not recommended.
Similar articles
- Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group.Rödel C, et al.Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.Lancet Oncol. 2015.PMID:26189067Clinical Trial.
- Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V.Fernández-Martos C, et al.J Clin Oncol. 2010 Feb 10;28(5):859-65. doi: 10.1200/JCO.2009.25.8541. Epub 2010 Jan 11.J Clin Oncol. 2010.PMID:20065174Clinical Trial.
- Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J, Mahé M, Bécouarn Y, Dupuis O, Lledo G, Seitz J, Bedenne L, Gourgou-Bourgade S, Juzyna B, Conroy T, Gérard J.Azria D, et al.Ann Oncol. 2017 Oct 1;28(10):2436-2442. doi: 10.1093/annonc/mdx351.Ann Oncol. 2017.PMID:28961836Clinical Trial.
- Radiochemotherapy in rectal cancer: the role of oxaliplatin.Gerard JP, Glynne-Jones R, Blackstock W, Aschele C, van de Velde C.Gerard JP, et al.Colorectal Dis. 2003 Nov;5 Suppl 3:29-35. doi: 10.1046/j.1463-1318.5.s3.4.x.Colorectal Dis. 2003.PMID:23573558Review.
- Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali AM, Moretti L, Troiani T, Ciardiello F, Hendlisz A, Sclafani F.Giunta EF, et al.Cancer Treat Rev. 2021 May;96:102177. doi: 10.1016/j.ctrv.2021.102177. Epub 2021 Mar 16.Cancer Treat Rev. 2021.PMID:33798955Review.
Cited by
- Phase II study of long-course chemoradiotherapy followed by consolidation chemotherapy as total neoadjuvant therapy in locally advanced rectal cancer in Japan: ENSEMBLE-2.Kagawa Y, Ando K, Uemura M, Watanabe J, Oba K, Emi Y, Matsuhashi N, Izawa N, Muto O, Kinjo T, Takemasa I, Oki E.Kagawa Y, et al.Ann Gastroenterol Surg. 2024 Aug 3;8(6):1067-1075. doi: 10.1002/ags3.12848. eCollection 2024 Nov.Ann Gastroenterol Surg. 2024.PMID:39502728Free PMC article.
- The evolving treatment paradigm of locally advanced rectal cancer: a narrative review.Awawda M, Taha T, Salman S, Billan S, Hijab A.Awawda M, et al.J Gastrointest Oncol. 2022 Aug;13(4):2033-2047. doi: 10.21037/jgo-22-13.J Gastrointest Oncol. 2022.PMID:36092339Free PMC article.Review.
- Preoperative Intensified Chemoradiation with Intensity-Modulated Radiotherapy and Simultaneous Integrated Boost Combined with Capecitabine in Locally Advanced Rectal Cancer: Long-Term Outcomes of a Real-Life Multicenter Study.Lupattelli M, Palazzari E, Polesel J, Chiloiro G, Angelicone I, Panni V, Caravatta L, Di Biase S, Macchia G, Niespolo RM, Franco P, Epifani V, Meldolesi E, de Giacomo F, Lucarelli M, Montesi G, Mantello G, Innocente R, Osti MF, Gambacorta MA, Aristei C, De Paoli A.Lupattelli M, et al.Cancers (Basel). 2023 Dec 4;15(23):5702. doi: 10.3390/cancers15235702.Cancers (Basel). 2023.PMID:38067405Free PMC article.
- Unveiling the profound advantages of total neoadjuvant therapy in rectal cancer: a trailblazing exploration.Jung KU, Kim HO, Kim H, Lee D, Cheong C; on the behalf of Korean Society of Korean Society of Coloproctology.Jung KU, et al.Ann Surg Treat Res. 2023 Dec;105(6):341-352. doi: 10.4174/astr.2023.105.6.341. Epub 2023 Nov 29.Ann Surg Treat Res. 2023.PMID:38076602Free PMC article.Review.
- A novel strategy of radiofrequency hyperthermia (neothermia) in combination with preoperative chemoradiotherapy for the treatment of advanced rectal cancer: a pilot study.Shoji H, Motegi M, Osawa K, Okonogi N, Okazaki A, Andou Y, Asao T, Kuwano H, Takahashi T, Ogoshi K.Shoji H, et al.Cancer Med. 2015 Jun;4(6):834-43. doi: 10.1002/cam4.431. Epub 2015 Feb 9.Cancer Med. 2015.PMID:25664976Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources